Disproportionate Reduction of Serotonin Transporter May Predict the Response and Adherence to Antidepressants in Patients with Major Depressive Disorder: A Positron Emission Tomography Study with 4-[^18F]-ADAM

Yi-Wei Yeh, MD; Pei-Shen Ho, MD, MS; Shin-Chang Kuo, MD; Chun-Yen Chen, MD; Chih-Sung Liang, MD; Che-Hung Yen, MD; Chang-Chih Huang, MD; Kuo-Hsing Ma, PhD; Chyng-Yann Shiue, PhD; Wen-Sheng Huang, MD; Jia-Fwu Shyu, MD, PhD; Fang-Jung Wan, MD, PhD; Ru-Band Lu, MD; San-Yuan Huang, MD, PhD

Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan (Drs Yeh, Kuo, Chen, Liang, and S-Y Huang); Department of Psychiatry, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan (Drs Yeh, Kuo, Chen, Shyu, Wan, and S-Y Huang); Department of Psychiatry, Beitou Branch, Tri-Service General Hospital, Taipei, Taiwan (Drs Ho and Liang); Department of Neurology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan (Dr Yen); Department of Psychiatry, Taipei Branch, Buddhist Tzu Chi General Hospital, New Taipei, Taiwan (Dr C-C Huang); Department of Biology & Anatomy, National Defense Medical Center, Taipei, Taiwan (Professor Ma and Dr Shyu); Department of Nuclear Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan (Professor Shiue and Dr W-S Huang); Department of Nuclear Medicine, Changhua Christian Hospital, Changhua, Taiwan (Dr W-S Huang); Department of Psychiatry, National Cheng Kung University, Tainan, Taiwan (Dr Lu).

Correspondence: San-Yuan Huang, MD, PhD, Professor and Attending Psychiatrist, Department of Psychiatry, Tri-Service General Hospital, National Defense Medical Center, No. 325, Sec. 2, Cheng-Kung Road, Nei-Hu District, Taipei, 11490, Taiwan (hsy@ndmctsgh.edu.tw).

Abstract

Background: Many lines of evidence suggest the role of serotonin transporter (SERT)-mediated reuptake of serotonin in the pathophysiology and treatment of major depressive disorder (MDD). This study aimed to examine whether the pretreatment of SERT binding potential or SERT binding ratio between terminal projection regions relative to the midbrain raphe nuclei was associated with treatment outcomes to SERT-targeted antidepressants.

Methods: We recruited 39 antidepressant-naïve patients with MDD and 39 healthy controls. Positron emission tomography with N,N-dimethyl-2-(2-amino-4-[^18F]fluorophenylthio)benzylamine (4-[^18F]-ADAM) was used to measure in vivo SERT availability prior to antidepressant treatment. The 21-item Hamilton Depression Rating Scale (HDRS) was used to assess the severity of depression from baseline to week 6. All the patients with MDD had HDRS scores of 18 or more.
Results: Pretreatment SERT binding in the thalamus and striatum positively correlated with an early reduction in HDRS scores at week 3. Nonresponders and dropout patients showed a proportionate reduction in SERT binding in the terminal projection regions and midbrain compared to healthy controls. In contrast, a disproportionate reduction in SERT binding in the terminal projection regions relative to midbrain was observed in responders.

Conclusions: The results of this study suggested that a disproportionate reduction in SERT binding between terminal projection regions and midbrain may predict better treatment outcomes in patients with MDD.

Keywords: adherence, antidepressant response, major depressive disorder, positron emission tomography, serotonin transporter

Introduction

Many lines of evidence suggest that serotonin transporter (SERT) plays an important role in the pathophysiology of major depressive disorder (MDD) and the therapeutic actions of SERT-targeted antidepressants (Owens and Nemeroff, 1994; Mann, 2013) that exert their function by blocking the SERT, thereby increasing serotonin (5-hydroxytryptamine [5-HT]) levels in the synapses of serotonergic projection terminals. The involvement of SERT gene (solute carrier family 6 (neurotransmitter transporter), member 4 [SLC6A4]) variants such as 5-hydroxytryptamine transporter-linked polymorphic region [5-HTTLPR] and S1m2 variable number tandem repeat in antidepressant efficacy has been widely investigated. However, the results are controversial and inconsistent across different ethnic populations (Ng et al., 2013). Furthermore, two meta-analysis studies reported a non-significant correlation between SLC6A4 variants and antidepressant efficacy (Kato and Serretti, 2010; Niitsu et al., 2013). Epigenetic evidence in peripheral leukocytes has shown a higher methylation rate of the SLC6A4 gene in drug-free patients with MDD, which may be associated with better therapeutic responses to antidepressants (Domschke et al., 2014; Okada et al., 2014). However, DNA methylation in peripheral blood cells may not be a reflection of that in the brain. Hence, in vivo imaging studies are necessary to examine the differences in SERT expression relative to the response to antidepressants.

The majority of SERT imaging studies have shown that patients with MDD have reduced SERT binding in a major depressive episode (MDE; Newberg et al., 2005, 2012; Parsey et al., 2006b; Reimold et al., 2008; Selvaraj et al., 2011; Ho et al., 2013; Gryglewski et al., 2014); however, there are some inconsistent reports of unaltered (Meyer, 2007) and the mixed binding of dopamine transporters (Meyer, 2007) and the mixed binding of the SERT and dopamine transporters (Meyer, 2007) and the mixed binding of the SERT and dopamine transporters may mask the true levels of SERT binding. Although [11C][+]McN5652 has higher selectivity for SERT compared with the other monoamine transporters, it may not be a reflection of that in the brain. Hence, in vivo imaging studies are necessary to examine the differences in SERT expression relative to the response to antidepressants.

The major drawback of these studies is the use of nonspecific SERT radioligands, such as [11C][+]McN5652 and [11C]β-CIT. For example, [11C][+]β-CIT has near equal affinity for the SERT and dopamine transporters (Meyer, 2007) and the mixed binding of the SERT and dopamine transporters may mask the true levels of SERT binding. Although [11C]β-CIT has higher selectivity for SERT compared with the other monoamine transporters, it has a low ratio of specific binding relative to free and nonspecific binding (Brust et al., 2006). A recent PET study that used the SERT-selective radioligand [11C] 3-amino-4-(2-dimethylaminomethylphenylsulfanyl)benzonitrile ([11C]DASB) reported no association between pretreatment SERT binding levels and the 3-week SSRI treatment response in patients with MDD (Lanzenberger et al., 2012). Hence, it remained to be elucidated whether the levels of SERT in drug-naïve patients are associated with treatment response and premature withdrawal from antidepressant treatment. The SERT binding in axon-projecting areas can be modulated by the tonic firing of serotonergic neurons through 5-hydroxytryptamine (serotonin) receptor 1A [5-HT1A] autoreceptors. This has been suggested as a potential mechanism of antidepressant action (Lanzenberger et al., 2012). Therefore, a biomarker to predict SERT-targeted antidepressant efficacy should not be limited to regional SERT binding, but should also measure the interplay of SERT binding in terminal-projection regions and midbrain raphe nuclei.
In the present study, we used PET with the SERT-selective radioligand N,N-dimethyl-2-(2-amino-4-[\(^{18}\)F]fluorophenylthio) benzylamine (4-[\(^{18}\)F]-ADAM) to measure in vivo SERT binding in the human brain (Shiue et al., 2003; Huang et al., 2010; Huang et al., 2013). After completing the PET scan, patients with MDD were administered a SERT-targeted antidepressant and a 6-week naturalistic follow-up. The study aimed to examine whether pre-treatment regional SERT binding or terminal projection region/midbrain SERT binding ratios correlated with an early reduction in depressive symptoms. Secondly, it aimed to investigate whether the pretreatment levels of regional SERT binding or SERT binding ratios predicted responders, nonresponders, and dropout patients.

**Method**

**Participants**

We used the Chinese version of the modified Schedule of Affective Disorder and the Schizophrenia-Lifetime (SADS-L) to screen psychiatric conditions in all participants (Endicott and Spitzer, 1978; Huang et al., 2004). The inclusion criteria for patients with MDD were as follows: (1) age between 20 to 65 years; (2) meeting MDD according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR); (3) a score of ≥18 on the 21-item Hamilton Depression Rating Scale (HDRS) as indicative of moderate to severe MDD (Hamilton, 1960). The exclusion criteria for patients with MDD were as follows: (1) patients diagnosed with other comorbid Axis I and/or Axis II disorders, with the exception of patients with nicotine dependence; (2) HDRS score of <18, as is indicative of a mild degree of depression; (3) significant physical illness; (4) women who were pregnant or lactating; (5) previous head trauma with loss of consciousness, epilepsy, and/or thyroid disease; (6) previous exposure to psychotropic medication, such as, antidepressants, mood stabilizers, or antipsychotics.

Thirty-nine healthy volunteers were recruited from the community. They were free of past or present major or minor mental illness, as determined by the SADS-L semi-structured interview, and none of the first-degree relatives of the control subjects had a history of psychiatric disorders, substance abuse/dependence, or attempted suicide. Thirty-nine patients with MDD were recruited from Tri-Service General Hospital. PET imaging was arranged after informed consent was obtained. After completing a PET scan, patients with MDD began 6 weeks of treatment with an open-label SERT-targeted antidepressant (either paroxetine [20–40 mg], venlafaxine [75–150 mg], or duloxetine [30–60 mg]) with a prospectively naturalistic follow-up. Some participants were recruited from a previous study (Yeh et al., 2014) and agreed to receive a naturalistic follow-up. The 21-item HDRS was used to assess the severity of depression from baseline to endpoint (week 6); these time points are often considered clinically important for treatment response (Papakostas et al., 2006; Lin et al., 2011; Lanzenberger et al., 2012). A responder was defined as a patient with a reduction ≥50% in the HDRS score between baseline and week 6, and a nonresponder was defined as a patient with a reduction <50% in the HDRS score between baseline and week 6. Adherence was defined as the act of filling a new prescription or refilling prescriptions on time, whereas nonadherence was defined as the discontinuation of filling or refilling prescriptions before the 6 week endpoint of treatment. The protocol was approved by the Institutional Review Board for the Protection of Human Subjects at the Tri-Service General Hospital in Taipei, Taiwan (Figure 1).

**PET Procedure**

The preparations for 4-[\(^{18}\)F]-ADAM synthesis were carried out in our PET Current Good Manufacturing Practice laboratory with an automated synthesizer as previously described (Peng et al., 2008); the synthesizer was inspected by the Council of Atomic Energy and the Department of Health, Taiwan. All participants underwent a low-dose computed tomography (CT) scan (130 kVp, 50 mAs, 0.8 s tube rotation, 4 mm slice collimation, and pitch 3) and then a static PET scan in three-dimensional mode using a BIOGRAPH PET/CT scanner (Biograph Duo, Siemens). Total PET imaging began at 120 to 140 min (total 20 min) after intravenous bolus injection of 7.94 ± 1.13 mCi 4-[\(^{18}\)F]-ADAM. This scanner had a transverse field-of-view of 58.5 cm, an axial field-of-view of 15.5 cm, and a spatial resolution of 4.8 mm. PET images were reconstructed in a 512x512x64 matrix with a pixel size of 0.519x0.519x2.4 mm using the ordered subset expectation maximization method (six iterations and 16 subsets) with a Gaussian filter of 3 mm full-width half maximum.

**PET Data Acquisition**

PET images were analyzed with commercial PMOD software for Windows (version 3.0, PMOD Technologies Ltd). The PET image from each subject was automatically co-registered with the corresponding individual CT scan and was then manually adjusted by an experienced physician. The individual CT images provide an anatomical reference, and regions of interest (ROIs) were defined on reconstructed and summed PET images. The ROIs were drawn over the midbrain, striatum, thalamus, and prefrontal cortex (PFC), where loci of serotonergic cell bodies (e.g. midbrain) and the main projection regions (e.g. striatum, thalamus, PFC) could be found. We used the cerebellum as a background reference because of its low SERT concentration when compared to other brain regions. To reduce the confounding effects of SERT binding in the cerebellum, we only delineate the posterior half of the cerebellar cortex and exclude the white matter.
and vermis. The non-displaceable binding potential (BP\textsubscript{ND}) of 4-\([18F]\)-ADAM was quantified using a ratio method by comparing a specifically-bound radioligand to a nondisplaceable radioligand in brain tissue at equilibrium as previously described (Huang et al., 2013; Yeh et al., 2014). We applied the time period at 120–140 min for the transient equilibrium ratio model. The BP\textsubscript{ND} of 4-\([18F]\)-ADAM in the target region was calculated by subtracting the tissue radioligand activity in the nondisplaceable region (C\textsubscript{ND}) from the tissue radioligand activity in the target region (C\textsubscript{ROI}), and then dividing the result by the tissue radioligand activity in the nondisplaceable region. The equation was defined as follows: \( \text{BP} = \frac{\text{C}_{\text{ROI}} - \text{C}_{\text{ND}}}{\text{C}_{\text{ND}}} \) (Ichise et al., 2001; Innis et al., 2007). The investigator using FMOd software to analyze images was blinded to all participant information.

**Statistical Analysis**

The continuous variables of the demographic data between groups were analyzed with either a Student’s t-test or one-way analysis of variance. Nominal differences in the demographic data between groups were examined with the Pearson \( \chi^2 \) test or Fisher’s exact test. BP\textsubscript{ND} data were analyzed by a linear mixed-effects model (McCulloch et al, 2008), with brain region and diagnostic group as fixed effects and subjects as the random effect (Parsey et al., 2006a, 2006b; Miller et al., 2008; Miller et al., 2013; Yeh et al., 2014). To assess the effects of demographic data, we successively set age, sex, smoking status, and body mass index (BMI) as other fixed effects in the linear mixed-effects models. A Bonferroni correction was used for multiple comparisons in the post hoc analysis. We used Spearman’s rank correlation to analyze the relationship between pretreatment regional levels of SERT BP\textsubscript{ND} and the reduction in the HDRS scores. A \( p \)-value < 0.05 was considered statistically significant (two-tailed).

A nonparametric analysis was applied in order to examine the differences in the pretreatment levels of regional SERT BP\textsubscript{ND} and SERT BP\textsubscript{ND} ratios in the terminal projection area/midbrain raphe nuclei among depressed subgroups and healthy controls. Due to the comparisons of SERT binding in the four ROIs and the three SERT binding ratios among the different groups (controls, responders, nonresponders, and dropouts), a conservative \( p \)-value of less than 0.05/7 \( = \) 0.007 was considered significant for multiple comparisons. We used Hedges’ \( g \) to compute the effect size between two groups. Small, medium, and large effect sizes were defined, respectively, as 0.2 \( \leq \) Hedges’ \( g \) < 0.5, 0.5 \( \leq \) Hedges’ \( g \) < 0.8, and Hedges’ \( g \) \( \geq \) 0.8. Receiver operator characteristic (ROC) curves were obtained and the area under the curve (AUC) was calculated for each regression model. All data were analyzed with SPSS software for Windows (version 17, SPSS).

**Results**

**Demographic and Clinical Characteristics**

The characteristics of all of the participants are summarized in Table 1. The age of the controls ranged from 21–62 years (mean ± standard deviation (SD), 32.3 ± 8.3 years; 21 men and 18 women) and the age of the patients with MDD ranged from 20–60 years (mean ± SD, 34.3 ± 11.5 years; 20 men and 19 women). Twenty-one patients with MDD completed the 6-week course of antidepressant treatment, and 18 patients with MDD dropped out (Figure 1). Among the 21 patients with MDD who completed the 6-week treatment course, the response rate was 57.1%. There were no significant differences in age, onset age, sex, BMI, smoking status, education years, or baseline HDRS scores among the responders, nonresponders, and dropout patients with MDD. A higher number of MDEs were seen in the dropout group than in the completed-treatment group. There were no significant differences in the mean injection dose of 4-\([18F]\)-ADAM among the groups. The types of antidepressants and their mean dosages used in the present study did not significantly differ among the responders, nonresponders, and dropout patients (Supplemental Table 1).

**Possible Effects of Demographic Data and Current MDD on Regional SERT Binding**

A scatter plot of the BP\textsubscript{ND} values from the four ROIs in the healthy controls and depressed subgroups is presented in Figure 2. By using linear mixed-effects models with brain region and diagnostic group as the fixed effects and subjects as the random effect, we found a significant effect of brain region on SERT binding (\( F = 348.953, df = 3,231, p < 0.001 \)). The values of BP\textsubscript{ND} in the order of highest to lowest, in the four ROIs was midbrain > thalamus > striatum > PFC. Across the four ROIs, BP\textsubscript{ND} was significantly different according to the diagnosis of current MDD (\( F = 11,357, df = 1,76, p = 0.001 \)). A post hoc analysis demonstrated significantly lower BP\textsubscript{ND} values in the midbrain (\( t = -3.480, df = 1,152, uncorrected p < 0.001 \)), thalamus (\( t = -4.204, df = 1,152, uncorrected p < 0.001 \)), and striatum (\( t = -2.821, df = 1,152, uncorrected p = 0.005 \)) in patients with MDD compared with healthy controls. Furthermore, the effect of current major depression on BP\textsubscript{ND} remained significant in the midbrain, thalamus, and striatum after Bonferroni corrections for multiple comparisons (Bonferroni-adjusted \( p = 0.003, <0.001, and 0.022, respectively \)). To further assess the effects of the demographic data, we successively set age, sex, smoking status, and BMI as other fixed effects in the linear mixed-effects models. Across the four ROIs, there was no effect of age (\( F = 1.564, df = 1,75, p = 0.215 \)) or sex (\( F = 1.732, df = 1,75, p = 0.192 \)) on SERT binding in the combined depressed and control groups. BMI (\( F = 0.884, df = 1,75, p = 0.350 \)) did not significantly influence SERT binding, and there was no effect of cigarette smoking on SERT binding (\( F = 0.129, df = 1,75, p = 0.720 \)).

Because nicotine dependence might confound the results, we further applied a stratification analysis according to cigarette smoking status. A significant effect of brain region on SERT binding in smokers (\( F = 52.467, df = 3,60, p < 0.001 \)) and nonsmokers (\( F = 336.854, df = 3,168, p < 0.001 \)) remained. A significant effect of the diagnosis of current MDD on SERT binding in smokers (\( F = 7.960, df = 1,19, p = 0.011 \)) and nonsmokers (\( F = 5.422, df = 1,55, p = 0.024 \)) remained. There was no effect of age, sex, or BMI on SERT binding across the four ROIs in smokers or in nonsmokers (all \( p \)-values > 0.05).

**The Association of Regional SERT BP\textsubscript{ND} or Projection Area/Midbrain SERT BP\textsubscript{ND} Ratios with Early Response to Antidepressants**

Within the completed treatment group (\( n = 21 \)), we observed that SERT binding in the thalamus (Spearman’s \( \rho \) coefficient = 0.518, \( p = 0.016 \)) and striatum (Spearman’s \( \rho \) coefficient = 0.438, \( p = 0.047 \)) positively correlated with a reduction in HDRS scores at week 3 (Figure 3, Supplemental Table 2) but not at the other weeks. We calculated the SERT binding ratio by dividing the SERT BP\textsubscript{ND} in the terminal projection area by the SERT BP\textsubscript{ND} in the midbrain. The projecting areas/midbrain SERT BP\textsubscript{ND} ratios...
| Table 1. Clinical and demographic characteristics of the participants |
|---|---|---|
| Healthy controls (n = 39) | MDD (n = 39) | Healthy controls vs MDD |
| Male, % (male/female) | 38.9% (21/18) | 51.3% (20/19) | 0.05 | 0.82 |
| Smoker, % (smoker/nonsmoker) | 12.8% (5/34) | 41.0% (16/23) | 7.89 | 0.005** |
| First episode, % (first/recurrent) | - | 56.4% (22/17) | - | - |
| | | | | 0.88 | 0.70 |
| Antidepressant |
| Paroxetine | - | 22 (56.4) | - | - |
| Venlafaxine | - | 15 (38.5) | 9 (75.0) | 6 (66.7) |
| Duloxetine | - | 2 (5.1) | 7 (38.9) | 4.56 | 0.30 |
| Mean ± SD | Mean ± SD | t (df = 1) | p | Mean ± SD | Mean ± SD | Mean ± SD |
| Age (years) | 32.3 ± 8.3 | 34.3 ± 11.5 | -0.88 | 0.38 | 35.1 ± 13.2 | 33.4 ± 8.5 | 34.2 ± 12.1 | 0.05 | 0.95 |
| Onset age (years) | - | 28.4 ± 9.8 | - | - | 31.1 ± 10.9 | 31.8 ± 7.6 | 24.9 ± 9.3 | 2.24 | 0.12 |
| Education (years) | 16.5 ± 2.1 | 13.9 ± 2.7 | 4.65 | <0.001*** |
| Body mass index (kg/m²) | 23.4 ± 3.5 | 22.7 ± 3.5 | 0.85 | 0.40 | 23.5 ± 4.1 | 23.1 ± 3.4 | 22.0 ± 3.2 | 0.70 | 0.51 |
| Number of MDE | - | 1.7 ± 0.9 | - | - | 1.4 ± 0.7 | 1.2 ± 0.4 | 2.1 ± 1.1 | 3.72 | 0.03* |
| Number of suicide attempts | - | 0.9 ± 1.3 | - | - | 0.4 ± 0.9 | 1.0 ± 1.5 | 1.1 ± 1.5 | 1.05 | 0.36 |
| Baseline HDRS score | 0.4 ± 1.1 | 27.8 ± 5.4 | -30.8 | <0.001*** |
| Dose of 4-[18F]-ADAM (mCi) | 8.1 ± 1.2 | 7.8 ± 1.0 | 128 | 0.20 | 7.8 ± 0.8 | 8.1 ± 0.9 | 7.6 ± 1.2 | 0.60 | 0.55 |

MDD, major depressive disorder; MDE, major depressive episode; HDRS, 21-item Hamilton Depression Rating Scale; SD, standard deviation; df, degree of freedom. Bold numbers indicate significance.

*a Fisher’s exact test.

*p<0.05, **p<0.01, ***p<0.001 is considered as significant.
did not show any correlations with reductions in HDRS scores (Supplemental Table 2).

The Association of Regional SERT BPND or Projection Area/Midbrain SERT BPND Ratios in Association with Outcome to Antidepressants at Week 6

The SERT BPND did not differ among responders, nonresponders, and dropout patients across the four ROIs. However, SERT binding in the thalamus and striatum was significantly lower in dropout patients compared to healthy controls \((z = 2.05, p < 0.05)\) compared to healthy controls. Small, medium, and large effect sizes were defined respectively as 0.2 ≤ Hedges’ \(g\) < 0.5, 0.5 ≤ Hedges’ \(g\) < 0.8, and Hedges’ \(g\) ≥ 0.8. We coded healthy controls, responders, nonresponders, and dropout patients as an ordinal variables 0, 1, 2, and 3, respectively. The Spearman’s rank correlations between the rank order and SERT binding were \(ρ = -0.417, p < 0.001\) for thalamus; \(ρ = -0.307, p = 0.005\) for striatum. PFC, prefrontal cortex.

The Prediction of Responders Based on Projection Area/Midbrain SERT BPND Ratios

The ROC curve and the AUC are presented in Figure 5A and B. The AUC for the logistic regression models for each projection area/midbrain SERT BPND ratios among the healthy controls, nonresponders, and dropout patients. There were no differences in the SERT BPND ratios among the healthy controls, nonresponders, and dropout patients.
area/midbrain SERT BP\textsubscript{ND} ratios is presented in Table 2. The striatum/midbrain SERT BP\textsubscript{ND} ratio predicted responders versus non-responders (AUC = 0.76, \( p = 0.047 \), Table 2, Figure 5A). We found that the thalamus/midbrain SERT BP\textsubscript{ND} ratio can distinguish the responder group from the “other” group (AUC = 0.78., \( p = 0.006 \), Table 2, Figure 5B). Both the striatum/midbrain (AUC = 0.75, \( p = 0.014 \)) and PFC/midbrain (AUC = 0.73, \( p = 0.026 \)) SERT BP\textsubscript{ND} ratios predicted the responders versus the “other” group. The predictive power of SERT BP\textsubscript{ND} ratios was fair because all the AUC values were greater than 0.7.

**Discussion**

Our naturalistic cohort study of 4-\([18F]\)-ADAM PET imaging in antidepressant-naïve patients with MDD demonstrated that greater pretreatment levels of SERT binding in the thalamus and striatum are associated with a greater reduction in HDRS scores at the 3-week stage of treatment. Our findings regarding the prediction of early improvement in depressive symptoms was in accordance with those of a previous study that used SPECT with the nonspecific SERT radioligand \([\text{[123I]}-\text{β-CIT]}\) (Kugaya et al., 2004).
They showed that higher levels of SERT binding in the diencephalon, including the thalamus and hypothalamus, predict a better 4-week treatment response to SSRIs. However, our findings were inconsistent with those of a study that used PET with the SERT-selective radioligand \( ^{125}\)I-DASB (Lanzenberger et al., 2012) and that revealed no association between any regional SERT binding and reduction in HDRS scores at week 3. Although we found that the SERT BPND was lower in the midbrain, thalamus, and striatum in patients with MDD compared with healthy controls, similar to the findings of previous reports (Newberg et al., 2005, 2012; Parsley et al., 2006b; Reimold et al., 2008; Selvaraj et al., 2011; Ho et al., 2013; Nye et al., 2013; Gryglewski et al., 2014), we did not find any differences in SERT BPND across the four ROIs between responders and nonresponders. This suggested that pretreatment SERT availability might contribute to the initial change in HDRS scores in the first 3 weeks; nevertheless, the final therapeutic efficacy may be regulated by another mechanism.

As previous studies did not recruit healthy controls (Kugaya et al., 2004; Lanzenberger et al., 2012), the differences among responders, nonresponders, and healthy controls could not be investigated. To the best of our knowledge, this is the first study to explore whether regional SERT binding and SERT binding ratios differ between healthy controls and depressed subgroups that were categorized by their outcomes to antidepressant treatment, including responders, nonresponders, and dropout patients. In the present study, we observed a trend towards reduced SERT availability, in order, from healthy controls to responders and nonresponders. This suggested that pretreatment SERT availability might contribute to the initial change in HDRS scores in the first 3 weeks; nevertheless, the final therapeutic efficacy may be regulated by another mechanism.

| Table 2. Predictive Ability of Serotonin Transporter (SERT) Non-displaceable Binding Potential (BPND) Ratios to Distinguish Responders from Nonresponders or “Other” Group. |
|----------|---------|---------|---------|---------|--------|---------|---------|---------|---------|---------|---------|---------|---------|
| Cutoff point | Sensitivity (%) | Specificity (%) | Predictive power (%) | AUC (%) | p value | Cutoff point | Sensitivity (%) | Specificity (%) | Predictive power (%) | AUC (%) | p value |
| TH/MB ratio | 0.78 | 100 | 56 | 78 | 73 | 0.076 | 0.86 | 92 | 59 | 75 | 78 | 0.006** |
| ST/MB ratio | 0.76 | 83 | 67 | 78 | 73 | 0.047* | 0.77 | 83 | 70 | 77 | 75 | 0.014* |
| PFC/MB ratio | 0.31 | 92 | 56 | 74 | 71 | 0.102 | 0.31 | 92 | 59 | 75 | 73 | 0.026* |

The cutoff point of SERT BP ND as the predictor by plotting the proportion of true positive result (sensitivity) versus the proportion of false-positive results (1-specificity). The area under the curve (AUC) indicates area under the receiver operator characteristic (ROC) curves (\(p < 0.05, *p < 0.01\)). Other group indicates combined nonresponders and dropout subjects. MB, midbrain; PFC, prefrontal cortex; ST, striatum; TH, thalamus.

SERT-targeted antidepressant efficacy at week 6. The inconsistent results at the various response times (week 3 versus week 6) might be due to differences in the antidepressants used, because antidepressants have different efficacies and response times (Cipriani et al., 2009). Previous studies that defined 3 or 4 weeks as the treatment endpoints might have underestimated the number of responders (Kugaya et al., 2004; Lanzenberger et al., 2012). Therefore, our study analyzed antidepressant-naïve depressed patients and followed them for 6 weeks, which might be a more complete treatment course.

It was unclear why a disproportionate reduction of SERT BP ND between the projection regions and the midbrain raphe nuclei was associated with better clinical response after 6 weeks of antidepressant therapy in drug-naïve patients with MDD. We propose three possible mechanisms to explain this finding. First, the down-regulation of SERT in the serotonergic cell bodies and axon terminals takes longer than 4–6 weeks after administration of an antidepressant (Mirza et al., 2007; Descarrries and Riad, 2012). Higher pretreatment levels of SERT binding in projection regions (e.g. thalamus and striatum) may lead to greater occupancy by the antidepressant (Kugaya et al., 2004; Baldinger et al., 2014), thereby rapidly enhancing 5-HT levels in the thalamus and striatum, which could ameliorate depressive symptoms at an early stage. Lower pretreatment levels of SERT BPND in the midbrain might be a compensatory response to the fewer numbers of serotonergic axons and neurons in major depression in order to overcome the lower levels of 5-HT (Arango et al., 2002; Austin et al., 2002). The responders showed the lowest SERT binding in the midbrain and a smaller decline in SERT binding in projection regions, which suggested that responders had a superior compensatory response and neuronal plasticity in response to lower serotonin neurotransmission among patients with major depression (Celada et al., 2001; Artigas, 2013). These patients might therefore have a better response to antidepressants. Second, higher pretreatment levels of SERT BPND in the thalamus or striatum could be moderated by inhibitory gamma-aminobutyric acid or excitatory glutaminergic inputs from the cortex and suppressed by 5-HT1A autoreceptors in order to regulate the serotonergic neuron firing rate. After initiating SERT-targeted antidepressants (Artigas, 2013), the serotonergic tonic firing rate would be suppressed through 5-HT1A autoreceptors in the midbrain raphe nuclei (Celada et al., 2001), which would consequently activate serotonergic neurons and promote 5-HT neurotransmission in terminal areas (Descarrries and Riad, 2012). Therefore, the unequal reduction in the SERT density in terminal projection regions relative to the midbrain might be involved in therapeutic efficacy in MDD, and could aid in predicting the treatment outcomes of patients with MDD. Third, microRNA expression is down-regulated in the terminal projection.
regions in patients with depression and suicide (Smalheiser et al., 2012; Serafini et al., 2014) and up-regulated after the administration of antidepressants (Baudry et al., 2010; Issler et al., 2014). These findings suggest that microRNA might modulate the level of SERT and 5-HT$_1A$ receptor in response to antidepressant treatment.

Our naturalistic follow-up study raised the issue of non-adherence to antidepressant treatment. The 53.8% complete-treatment rate in our study was in line with previous studies showing that approximately 55% of the patients with depression maintained their complete antidepressant therapy during the first month, whereas the other patients prematurely discontinued medication (Brown et al., 2005; Wu et al., 2013). Adherence to the antidepressant is essential for therapeutic efficacy in patients with MDD (Demyttenaere, 1998; Pampallona et al., 2002). However, earlier studies investigating adherence to antidepressants have focused on personal insight, education level, and concerns about the antidepressant side effects without assessing the biological factors in dropout patients (Pampallona et al., 2002; Vergouwen et al., 2003). Our results showed that SERT BP$_{ND}$ ratios did not differ between dropout patients and nonresponders, but a trend of greater decline in regional SERT binding was noted in dropout patients compared to nonresponders. This implied that the withdrawal from antidepressant in patients with major depression might not only be due to poor insight into the illness and medication but also because of a poor response to antidepressants, similar to nonresponders. Furthermore, a significant difference in the SERT BP$_{ND}$ ratios was observed between dropout patients and responders. Therefore, the SERT BP$_{ND}$ ratios between the terminal projection regions and the midbrain raphe nuclei might be a potential biomarker for prediction of responders versus nonresponders and dropouts. Because the predictive power of the SERT BP$_{ND}$ ratios was fair (75%–78%, Table 2), this biological evidence may help clinicians to more closely monitor those patients who have low thalamus/midbrain and striatum/midbrain SERT BP$_{ND}$ ratios while they are on antidepressant therapy.

Finally, the basal ganglia, including the striatum, are strongly interconnected with the cortex, thalamus, brain stem, and other brain areas. Among these, the corticobasal ganglia pathway plays a crucial role in the neuropathology of mood disorders (Marchand et al., 2012) and reward prediction (Tanaka et al., 2004), and could contribute to the response and decision of antidepressant adherence. Serotonin levels have been suggested to modulate cerebral glucose metabolism in patients with major depression (Smith et al., 2002, 2009; Geday et al., 2005). Regional SERT density can affect 5-HT levels in order to modulate glucose uptake in the subcortical and cortical regions, thus influencing the response and adherent behaviors of patients to antidepressants (Kennedy et al., 2007; Milak et al., 2009). As we previously mentioned, the higher projection region/midbrain BP$_{ND}$ ratios distinguished responders from nonresponders and dropout patients, and the disproportional reduction in SERT binding between terminal projection regions and the midbrain might be involved in the treatment outcome through the regulation of cerebral glucose metabolism. Although nicotine can inhibit 5-HT reuptake and stimulate 5-HT release in platelets (Rausch et al., 1989), which potentially increases SERT levels, previous imaging studies did not show a significant association between cigarette smoking and SERT availability (Staley et al., 2001; Ruhe et al., 2009; Erritzoe et al., 2010; Ho et al., 2013). Consistent with these studies, we did not find any associations between cigarette smoking and SERT binding.

A few limitations in our study should be addressed. First, we did not measure the plasma levels of the antidepressant or SERT occupancy by the antidepressant during the 6-week treatment course. The association between SERT occupancy by the antidepressant and antidepressant concentration could not be further analyzed. However, previous studies had shown that pretreatment SERT binding levels positively correlated with antidepressant occupancy (Baldinger et al., 2014). Hence, our result based on pretreatment SERT availability was able to predict the response to SERT-targeted antidepressants. Second, we recruited patients with MDD and treated them with common SERT-targeted antidepressants, including SSRIs, such as paroxetine, and serotonin-norepinephrine reuptake inhibitors (SNRIs), such as venlafaxine and duloxetine. The different antidepressants that we used in the present study may have had different affinities to norepinephrine transporter (NET). An antidepressant with a higher NET/SERT affinity ratio, such as duloxetine, might have a higher blockade of NET compared with other SNRIs and SSRIs. Thus, our prediction based on SERT binding might merely explain the SERT effect and not the NET effect. We could not rule out the effect of NET in the present study (Owens et al., 2008; Nogami et al., 2013), because pretreatment levels of NET binding and NET occupancy by the antidepressants might also contribute to therapeutic efficacy. Third, the dosage may also confound the outcome of antidepressant treatment. However, both SSRIs and SNRIs at their minimal standard therapeutic dosages show around 80% occupancy of the SERT (Meyer et al., 2001, 2004b), and higher dosages would result in a plateau effect of SERT occupancy. Even though the doses of the SERT-targeted antidepressants varied, the SERT occupancy by the antidepressants should be consistent with those in previous studies. In contrast, the occupancy of NET by SNRIs had a dose-dependent effect (Owens et al., 2008), and dosage of SNRIs may influence the therapeutic efficacy. Nevertheless, we did not observe any dosage differences among different types of antidepressants between responders and nonresponders. Fourth, our small sample size (n = 78) was insufficient to explore the association of SLC6A4 variant effects with each group’s SERT BP$_{ND}$. However, previous postmortem (Mann et al., 2000) and in vivo imaging studies (Parsey et al., 2006a; Ho et al., 2013) have shown no significant differences in 5-HTTLPR and STin2 variable number tandem repeat polymorphisms on SERT binding. Therefore, in vivo SERT availability might account for treatment response more than SLC6A4 variants in patients with MDD. Nevertheless, the effects of other genes or epigenetic modulations on SERT binding in the brain should be considered. Fourth, psychosocial problems and personality traits may also contribute to treatment response (Kaneda et al., 2011); however, we did not discuss this in the present study.

**Conclusion**

Taken together, our study provides new insight into pretreatment SERT availability and its association with treatment outcomes in patients with major depression. The disproportionate reduction in SERT binding in the projection area and in the midbrain raphe nuclei may be attributed to a response to antidepressants, whereas a proportionate reduction in SERT density may be associated with nonresponse and nonadherence to antidepressants. These findings may help clinicians to predict which patients may be nonresponsive or reluctant to adhere to SERT-targeted antidepressants treatment. For such patients, the use of other treatment strategies, including augmentation, use of antidepressants with other mechanisms of action, or
psychotherapy, is recommended. Supplemental Table 1. Dosages of antidepressants used in present study. Supplemental Table 2. Correlation between the reduction of HDRS score at each week and pretreatment regional SERT binding and SERT binding ratios.

Acknowledgements
This study was supported by grants from National Science Council of Taiwan (NSC97-2314-B-016-001-MY2, NSC99-2314-B-016-019-MY3) to Dr S-Y Huang (NSC100-2314-B-016-036-MY3) to Dr W-S Huang, from Tri-Service General Hospital (TSGH-C98-09-S02, TSGH-C99-008-9-S02, TSGH-C100-009-008-9-S02) to Drs Yeh and Chen, (TSGH-C101-122, TSGH-C102-120, TSGH-C103-133) to Dr S-Y Huang, and from Medical Affairs Bureau, Ministry of National Defense, Taiwan (DOD99-C04-04, DOD100-C09-03) to Drs Yeh and Chen, (MAB101-51, MAB-102-68) to Dr S-Y Huang. We would like to thank Miss Mei-Chen Shih and Yun-Hsin Lin for their assistance in the preparing this manuscript.

Statement of Interest
None.

Supplementary Material
For supplementary material accompanying this paper, visit http://www.ijnp.oxfordjournals.org/

References
Arango V, Underwood MD, Mann JJ (2002) Serotonin brain circuits involved in major depression and suicide. Prog Brain Res 136:443–453.
Artigas F (2013) Serotonin receptors involved in antidepressant effects. Pharmacol Ther 137:119–131.
Austin MC, Whitehead RE, Edgar CL, Janosky JE, Lewis DA (2002) Localized decrease in serotonin transporter-immunoreactive axons in the prefrontal cortex of depressed subjects committing suicide. Neuroscience 114:807–815.
Baldinger P, Kranz GS, Haeseler D, Savili M, Spies M, Philippe C, Austin MC, Whitehead RE, Edgar CL, Janosky JE, Lewis DA (2002) Serotonin receptors involved in antidepressant effects. Pharmacol Ther 137:119–131.
Artigas F (2013) Serotonin receptors involved in antidepressant effects. Pharmacol Ther 137:119–131.
Baudry A, Mouillet-Richard S, Schneider B, Launay JM, Kellermann O (2010) miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. Science 329:1537–1541.
Brown C, Battista DR, Bruhelman R, Sereika SS, Thase ME, Dunbar-Jacob J (2005) Beliefs about antidepressant medications in primary care patients: relationship to self-reported adherence. Med Care 43:1203–1207.
Brust P, Hesse S, Muller U, Szabo Z (2006) Neuroimaging of the serotonin transporter - possibilities and pitfalls. Curr Psychiatry Rev 2:111–119.
Cannon DM, Ichise M, Rollis D, Klaver JM, Gandhi SK, Charney DS, Manji HK, Drevets WC (2007) Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol Psychiatry 62:870–877.
Celada P, Puig MV, Casanovas JM, Guillauro G, Artigas F (2001) Control of dorsal raphe serotonergic neurons by the medial prefrontal cortex: Involvement of serotonin-1A, GABA(A), and glutamate receptors. J Neurosci 21:9917–9929.
Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori JM, McGuire H, Tansella M, Barbui C (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:746–758.
Demyttenaere K (1998) Noncompliance with antidepressants: who’s to blame? Int Clin Psychopharmacol 13(Suppl 2):S19–25.
Descarries L, Riad M (2012) Effects of the antidepressant fluoxetine on the subcellular localization of 5-HT1A receptors and SERT. Phil Trans R Soc B 367:2416–2425.
Domschke K, Tidow N, Schwarte K, Deckert J, Lesch KP, Arolt V, Zwanzer P, Baune BT (2014) Serotonin transporter gene hypomethylation predicts impaired antidepressant treatment response. Int J Neuropsychoph 17:1167–1176.
Endicott J, Spitzer RL (1978) A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 35:837–844.
Erlandsson K, Sivananthan T, Lui D, Spezzi A, Townsend CE, Mu S, Lucas R, Warrington S, Ell PJ (2005) Measuring SSRI occupancy of SERT using the novel tracer [123I]ADAM: a SPECT validation study. Eur J Nucl Mol Imaging 32:1329–1336.
Erritzoe D, Frokjaer VG, Haahr MT, Kalbitzer J, Svarer C, Holst KK, Hansen DL, Jernigan TL, Lehel S, Knudsen GM (2010) Cerebral serotonin transporter binding is inversely related to body mass index. Neuroimage 52:284–289.
Geday J, Hermansen F, Rosenberg R, Smith DF (2005) Serotonin modulation of cerebral blood flow measured with positron emission tomography (PET) in humans. Synapse 55:224–229.
Gryglewski G, Lanzenberger R, Kranz GS, Cumming P (2014) Meta-analysis of molecular imaging of serotonin transporters in major depression. J Cereb Blood Flow Metab 34:1096–1103.
Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62.
Ho PS, Ho KK, Huang WS, Yen CH, Shih MC, Shen LH, Ma KH, Huang SY (2013) Association study of serotonin transporter availability and SLC6A4 gene polymorphisms in patients with major depression. Psychiatry Res 212:216–222.
Hsieh PC, Lee IH, Yeh TL, Chen KC, Huang HC, Chen PS, Yang YK, Yao WJ, Lu RB, Chiu NT (2010) Distribution volume ratio of serotonin and dopamine transporters in euthymic patients with a history of major depression - a dual-isotope SPECT study. Psychiatry Res 184:157–161.
Huang SY, Lin WW, Ko HC, Lee JF, Wang TJ, Chou YH, Yin SJ, Lu RB (2004) Possible interaction of alcohol dehydrogenase and aldehyde dehydrogenase genes with the dopamine D2 receptor gene in anxiety-depressive alcohol dependence. Alcohol Clin Exp Res 28:374–384.
Huang WS, Huang SY, Ho PS, Ma KH, Huang YY, Yeh CB, Liu RS, Cheng CY, Shiue CY (2013) PET imaging of the brain serotonin transporters (SERT) with N,N-dimethyl-2-(2-amino-4-[18F]fluorophenylthio)benzylamine (4-[18F]-ADAM) in humans: a preliminary study. Eur J Nucl Mol Imaging 40:115–124.
Huang YY, Ma KH, Tseng TW, Chou TK, Ng H, Mirsalis JC, Fu YK, Chu TC, Huang WS, Shiue CY (2010) Biodistribution, toxicity and radiation dosimetry studies of the serotonin transporter radioligand 4-[18F]-ADAM in rats and monkeys. Eur J Nucl Med Mol Imaging 37:545–555.
Ichise M, Meyer JH, Yonekura Y (2001) An introduction to PET and SPECT neuroreceptor quantification models. J Nucl Med 42:755–763.
Innis RB, et al. (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533–1539.

Issler O, Haramat S, Paul ED, Maeno H, Navon I, Zwang R, Gil S, Mayberg HS, Dunlop BW, Menke A, Awatramani R, Binder EB, Deneris ES, Lowry CA, Chen A (2014) MicroRNA 135 is essential for chronic stress resiliency, antidepressant efficacy, and intact serotoninergic activity. Neuro 83:34–360.

Kaneda A, Yasui-Furukori N, Nakagami T, Sato Y, Kaneko S (2011) The influence of personality factors on paroxetine response time in patients with major depression. J Affect Disord 135:321–325.

Kato M, Serretti A (2010) Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 15:473–500.

Kennedy SH, Konarski JZ, Segal ZV, Lau MA, Bieling PJ, McIntyre RS, Mayberg HS (2007) Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. Am J Psych 164:778–788.

Klein N, Sacher J, Geiss-Granadina T, Attarbaschi T, Mossaheb N, Lanzenberger R, Potzi C, Holik A, Spindelegger C, Asenbaum S, Dudczak R, Tauscher J, Kasper S (2006) In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. Psychopharmacology (Berl) 188:263–272.

Kugaya A, Sanacora G, Staley JK, Malison RT, Bozkurt A, Khan S, Anand A, Van Dyck CH, Baldwin RM, Seibyl JP, Charney D, Innis RB (2004) Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. Biol Psychiatry 56:497–502.

Lanzenberger R, Kranz GS, Haeusler D, Akimova E, Lanzenberger R, Potzi C, Holik A, Spindelegger C, Asenbaum S, Dudczak R, Tauscher J, Kasper S (2006) In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. Psychopharmacology (Berl) 188:263–272.

Lehto SM, Tolmunen T, Joensuu M, Valkonen-Pulkki C, Aromaa A, Ahola P, Tiihonen J, Kuikka J, Vanninen R (2008) Brain serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. Psychopharmacology (Berl) 188:263–272.

Lehtonen J (2008) Changes in midbrain serotonin transporter availability in atypically depressed subjects after one year of psychotherapy. Neuroimage 63:874–881.

Lehtonen J, Tolmunen T, Joensuu M, Saarinen PI, Valkonen-Korhonen M, Vanninen R, Ahola P, Tiihonen J, Kuikka J (2008) Changes in midbrain serotonin transporter availability in atypically depressed subjects after one year of psychotherapy. Prog Neuropsychopharmacol Biol Psychiatry 202:161–167.

Lin CH, Lane HY, Chen CC, Joo SH, Yen CF (2011) Early prediction of fluoxetine response for Han Chinese inpatients with major depressive disorder. J Clin Psychopharmacol 31:187–193.

Mann JJ (2013) The serotoninergic system in mood disorders and suicidal behaviour. Phil Trans R Soc B 368:20120537.

Mann JJ, Huang YY, Underwood MD, Kassir SA, Oppenheim S, Malison RT, Bozkurt A, Khan S, Anand A, Van Dyck CH, Baldwin RM, Seibyl JP, Charney D, Innis RB (2004) Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. Biol Psychiatry 56:497–502.

Meyer JH, Wilson AA, Ginovart N, Goulding V, Kennedy J, Wilson AA (2004a) Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry 61:1271–1279.

Meyer JH, Wilson AA, Ginovart N, Goulding V, Hussey D, Hood K, Houle S (2001) Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Am J Psych 158:1843–1849.

Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, Houle S (2004b) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [(11)C]DASB positron emission tomography study. Am J Psych 161:826–835.

Mikulski MA, Pena D, Oquendo MA, Olvet DM, Eipper F, Malone K, Mann JJ (2009) Pretreatment regional brain glucose uptake in the midbrain on PET may predict remission from a major depressive episode after three months of treatment. Psychiatry Res 173:63–70.

Miller JM, Hesselgrave N, Ogden RT, Sullivan GM, Oquendo MA, Mann JJ, Parsey RV (2013) Positron emission tomography quantification of serotonin transporter in suicide attempters with major depressive disorder. Biol Psychiatry 74:287–295.

Miller JM, Oquendo MA, Ogden RT, Mann JJ, Parsey RV (2008) Serotonin transporter binding as a possible predictor of one-year remission in major depressive disorder. J Psychiat Res 42:1137–1144.

Miranza NR, Nielsen EO, Troelsen KB (2007) Serotonin transporter density and anxiolytic-like effects of antidepressants in mice. Prog Neuropsychopharmacol Biol Psychiatry 31:858–866.

Newberg AB, Amsterdam JD, Wintering N, Ploessl K, Swanson RL, Shults J, Alavi A (2005) 123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: a preliminary study. J Nucl Med 46:973–977.

Newberg AB, Amsterdam JD, Wintering N, Shults J (2012) Low brain serotonin transporter binding in major depressive disorder. Psychiatry Res 202:161–167.

Ng C, Sarris J, Singh A, Bousman C, Byron K, Peh LH, Smith DJ, Tan CH, Schweitzer I (2013) Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression. Hum Psychopharmacol 28:516–522.

Niitsu T, Fabbri C, Bentini F, Serretti A (2013) Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 45:183–194.

Nogami T, Takano H, Arakawa R, Ichimiyi T, Fujihara H, Kimura Y, Kodaka F, Sasaki T, Takahata K, Suzuki M, Nagashima T, Mori T, Shimada H, Fukuda H, Sekine M, Taboto A, Takahashi H, Ito H, Okubo Y, Suhara T (2013) Occupancy of serotonin and norepinephrine transporter by mirtazapine in patients with major depressive disorder: a positron emission tomography study with [(11)C]DASB and [(S,S)-(18)F]FMeNER-D(2). Int J Neuropsychopharmacol 16:937–943.

Nye JA, Purseille D, Plisson C, Voll RJ, Stehouwer JS, Votaw JR, Kilts CD, Goodman MM, Nemeroff CB (2013) Decreased brainstem and putamen SERT binding potential in depressed suicide attempters using [(11)C]-ZIENET PET imaging. Depress Anxiety 30:902–907.

Okada S, Morinobu S, Fuchikami M, Segawa M, Yokomitsu Y, Ohtsuka M, Nishikawa S, Inoue T, Kusumi I, Koyama T, Tsujiyama K, Terao T, Kubo Y, Mimura M (2014) The potential of SLC6A4 gene methylation analysis for the...
diagnosis and treatment of major depression. J Psychiat Res 53:47–53.

Owens MJ, Krulewicz S, Simon JS, Sheehan DV, Thase ME, Carpenter DJ, Flott Sj, Nemeroff CB (2008) Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. Neuropsychopharmacology 33:3201–3212.

Owens MJ, Nemeroff CB (1994) Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 40:288–295.

Pampalona S, Bollini P, Tibaldi G, Kupelnick B, Munizza C (2002) Patient adherence in the treatment of depression. Br J Psychiatry 180:104–109.

Parsey RV, Hastings RS, Oquendo MA, Hu X, Goldman D, Huang YY, Simpson N, Arcement J, Huang Y, Ogden RT, Van Heertum RL, Arango V, Mann J (2006a) Effect of a triallelic functional polymorphism of the serotonin-transporter-linked promoter region on expression of serotonin transporter in the human brain. Am J Psych 163:48–51.

Parsey RV, Hastings RS, Oquendo MA, Huang YY, Simpson N, Arcement J, Huang Y, Ogden RT, Van Heertum RL, Arango V, Mann J (2006b) Lower serotonin transporter binding potential in the human brain during major depressive episodes. Am J Psych 163:52–58.

Parsey RV, Kent JM, Oquendo MA, Richards MC, Pratap M, Cooper TR, Arango V, Mann J (2006c) Acute occupancy of brain serotonin transporter by sertraline as measured by [11C]DASB and positron emission tomography. Biol Psychiatry 59:821–828.

Peng CJ, Huang YY, Huang WS, Shiue CY (2008) An automated synthesis of N,N-dimethyl-2-(2-amino-4-[18F]fluorophenythio)benzylamine ([4-[18F]-ADAM) for imaging serotonin transporters. Appl Radiat Isot 66:625–631.

Rausch JL, Fefferman M, Ladsich-Rogers DG, Menard M (1989) Effect of nicotine on human blood platelet serotonin uptake and efflux. Prog Neuropsychopharmacol Biol Psychiatry 13:907–916.

Reimold M, Batra A, Knobel A, Smolka MN, Zimmer A, Mann K, Solbach C, Reischl G, Schwarzer F, Grunder G, Machulla HJ, Bares R, Heinz A (2008) Anxiety is associated with reduced central serotonin transporter availability in medicated patients with unipolar major depression: a [11C]DASB PET study. Mol Psychiatry 13:606–613, 557.

Reivich M, Amsterdam JD, Shiue CY (2004) PET brain imaging with [11C]([+)McN5652 shows increased serotonin transporter availability in major depression. J Affect Disord 82:321–327.

Ruhe HG, Booij J, Reitsma JB, Schene AH (2009) Serotonin transporter binding with [123I]beta-CIT SPECT in major depressive disorder versus controls: effect of season and gender. Eur J Nucl Med Mol Imaging 36:841–849.

Selvaraj S, Murthy NV, Bhagwagar Z, Bose SK, Hinz R, Grasby PM, Cowen P (2011) Diminished brain 5-HT transporter binding in major depression: a positron emission tomography study with [11C]DASB. Psychopharmacology (Berl) 213:555–562.

Serafini G, Pompili M, Hansen KF, Obrietan K, Dwivedi Y, Shomron N, Girardi P (2014) The involvement of microRNAs in major depression, suicidal behavior, and related disorders: a focus on miR-185 and miR-491-3p. Cell Mol Neurobiol 34:17–30.

Shiue GG, Choi SR, Fang P, Hou C, Acton PD, Cardi C, Saffer JR, Greenberg JH, Karp JS, Kung HF, Shiue CY (2003) N,N-dimethyl-2-(2-amino-4-(18F)fluorophenylthio)-benzylamine ([4-(18F)-ADAM): an improved PET radioligand for serotonin transporters. J Nucl Med 44:1890–1897.

Smallheiser NR, Lugli G, Rizavi HS, Torvik VI, Turecki G, Dwivedi Y (2012) MicroRNA expression is down-regulated and reorganized in prefrontal cortex of depressed suicide subjects. PLOS ONE 7:e33201.

Smith GS, Kramer E, Hermann C, Ma Y, Dhawan V, Chaly T, Eidelberg D (2009) Serotonin modulation of cerebral glucose metabolism in depressed older adults. Biol Psychiatry 66:259–266.

Smith GS, Ma Y, Dhawan V, Gunduz H, Carbon M, Kirshner M, Larson J, Chaly T, Belakheff A, Kramer E, Greenwald B, Kane JM, Laghrissi-Thode F, Pollock BG, Eidelber D (2002) Serotonin modulation of cerebral glucose metabolism measured with positron emission tomography (PET) in human subjects. Synapse 45:105–112.

Staley JK, Krishnan-Sarin S, Zoghbi S, Tamagnan G, Fujita M, Seibyl JP, Maciejewski PK, O’Malley S, Innis RB (2001) Sex differences in [123I][beta]-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse 41:275–284.

Tanaka SC, Doya K, Okada G, Ueda K, Okamoto Y, Yamawaki S (2004) Prediction of immediate and future rewards differentially recruits cortico-basal ganglia loops. Nat Neurosci 7:887–893.

Vergouwen AC, Bakker A, Katon WJ, Verheij TJ, Koerselman F (2003) Improving adherence to antidepressants: a systematic review of interventions. J Clin Psychiatry 64:1415–1420.

Wu CS, Shau WY, Chan HY, Lai MS (2013) Persistence of antidepressant adherence to antidepressants in patients with major depressive disorder in Taiwan. Gen Hosp Psychiatry 35:279–285.

Yeh YW, Ho PS, Chen CY, Kuo SC, Liang CS, Ma KH, Shiue CY, Huang WS, Cheng CY, Wang TY, Lu RB, Huang SY (2014) Incongruent reduction of serotonin transporter associated with suicide attempts in patients with major depressive disorder: a positron emission tomography study with 4-[(18F)]-ADAM. Int J Neuropsychoph. Advance online publication, in press. doi:10.1093/ijnj/pyu065.